Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean Lang

Showing results (41-50 of 53) with videos related to

Pageof 6
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|August 21, 2003
Most highly exposed seronegative men lack HIV-1-specific, IFN-gamma-secreting T cellsFlorian Hladik, Anthony Desbien, Jean Lang, et al.
Vaccine|April 25, 2006
Innate and adaptive cellular immunity in flavivirus-naïve human recipients of a live-attenuated dengue serotype 3 vaccine produced in Vero cells (VDV3)Violette Sanchez, Sophie Gimenez, Brian Tomlinson, et al.
The Pediatric Infectious Disease Journal|February 12, 2004
Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai childrenArunee Sabchareon, Jean Lang, Pornthep Chanthavanich, et al.
Vaccine|September 3, 2008
Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjectsBruno Guy, Nolwenn Nougarede, Sarah Begue, et al.
Transactions of the Royal Society of Tropical Medicine and Hygiene|July 16, 2010
A prospective cohort study of dengue infection in schoolchildren in Long Xuyen, Viet NamNguyen Thi Kim Tien, Christine Luxemburger, Nguyen Trong Toan, et al.
The American Journal of Tropical Medicine and Hygiene|February 5, 2009
Evaluation of interferences between dengue vaccine serotypes in a monkey modelBruno Guy, Veronique Barban, Nathalie Mantel, et al.
The American Journal of Tropical Medicine and Hygiene|July 26, 2002
Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple dosesArunee Sabchareon, Jean Lang, Pornthep Chanthavanich, et al.
Human Vaccines|October 3, 2006
Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypesFarshad Guirakhoo, Scott Kitchener, Dennis Morrison, et al.
Lancet (London, England)|September 15, 2012
Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trialArunee Sabchareon, Derek Wallace, Chukiat Sirivichayakul, et al.
Human Vaccines & Immunotherapeutics|July 11, 2013
Persistence of Th1/Tc1 responses one year after tetravalent dengue vaccination in adults and adolescents in SingaporeAnke Harenberg, Sarah Begue, Audrey Mamessier, et al.
Pageof 6

Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
Journal of Immunology (Baltimore, Md. : 1950)|August 21, 2003
Most highly exposed seronegative men lack HIV-1-specific, IFN-gamma-secreting T cellsFlorian Hladik, Anthony Desbien, Jean Lang, et al.
Vaccine|April 25, 2006
Innate and adaptive cellular immunity in flavivirus-naïve human recipients of a live-attenuated dengue serotype 3 vaccine produced in Vero cells (VDV3)Violette Sanchez, Sophie Gimenez, Brian Tomlinson, et al.
The Pediatric Infectious Disease Journal|February 12, 2004
Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai childrenArunee Sabchareon, Jean Lang, Pornthep Chanthavanich, et al.
Vaccine|September 3, 2008
Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjectsBruno Guy, Nolwenn Nougarede, Sarah Begue, et al.
Transactions of the Royal Society of Tropical Medicine and Hygiene|July 16, 2010
A prospective cohort study of dengue infection in schoolchildren in Long Xuyen, Viet NamNguyen Thi Kim Tien, Christine Luxemburger, Nguyen Trong Toan, et al.
The American Journal of Tropical Medicine and Hygiene|February 5, 2009
Evaluation of interferences between dengue vaccine serotypes in a monkey modelBruno Guy, Veronique Barban, Nathalie Mantel, et al.
The American Journal of Tropical Medicine and Hygiene|July 26, 2002
Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple dosesArunee Sabchareon, Jean Lang, Pornthep Chanthavanich, et al.
Human Vaccines|October 3, 2006
Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypesFarshad Guirakhoo, Scott Kitchener, Dennis Morrison, et al.
Lancet (London, England)|September 15, 2012
Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trialArunee Sabchareon, Derek Wallace, Chukiat Sirivichayakul, et al.
Human Vaccines & Immunotherapeutics|July 11, 2013
Persistence of Th1/Tc1 responses one year after tetravalent dengue vaccination in adults and adolescents in SingaporeAnke Harenberg, Sarah Begue, Audrey Mamessier, et al.
Pageof 6